At Pliant Therapeutics, we recognize that our success depends on the excellence of our people. With this in mind, we are highly vested in the recruitment, training and development of our employees.
We are looking for exceptional candidates who are dedicated to our corporate values and are interested in being a part of a team that is committed to developing a pipeline of innovative therapeutics to treat major unmet medical needs.
By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery.
Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
Pliant Therapeutics total Funding
Pliant Therapeutics latest funding size
Time since last funding
|a month ago|
Pliant Therapeutics investors
|Agent Capital, Cowen Healthcare Investments, Eventide Asset Management, SCubed Capital, Third Rock Ventures, Menlo Ventures, Schroder Adveq|